Literature DB >> 11896565

High telomerase activity correlates with the stabilities of genome and DNA ploidy in renal cell carcinoma.

Hideki Izumi1, Takahiko Hara, Atsunori Oga, Kenji Matsuda, Yuko Sato, Katsusuke Naito, Kohsuke Sasaki.   

Abstract

Malignant tumors have telomerase activity, which is thought to play a critical role in tumor growth. However, the relation between telomerase activity and genomic DNA status in tumor cells is poorly understood. In the present study, we examined telomerase activity in 13 clear cell type renal cell carcinomas (CRCCs) with similar clinicopathologic features by telomeric repeat amplification protocol assay (TRAP). Based on TRAP assay results, we divided the CRCCs into two groups: a high telomerase activity group and a low/no telomerase activity group. We then analyzed genomic aberration, DNA ploidy, and telomere status in these two groups by comparative genomic hybridization (CGH), laser scanning cytometry (LSC), and telomere-specific fluorescence in situ hybridization (T-FISH), respectively. CGH showed the high telomerase activity group to have fewer genomic changes than the low/no telomerase activity group, which had many genomic aberrations. Moreover, with LSC, DNA diploid cells were found more frequently in the high telomerase activity group than in the low/no telomerase activity group. In addition, T-FISH revealed strong telomere signal intensity in the high telomerase activity group compared with that of the low/no telomerase activity group. These results suggest that telomerase activity is linked to genomic DNA status and that high telomerase activity is associated with genomic stability, DNA ploidy, and telomere length in CRCC.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11896565      PMCID: PMC1550322          DOI: 10.1038/sj.neo.7900205

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  43 in total

1.  Telomerase activity and telomere lengths: alterations in renal cell carcinomas.

Authors:  R Dahse; W Fiedler; K Junker; A Schlichter; J Schubert; U Claussen
Journal:  Kidney Int       Date:  1999-10       Impact factor: 10.612

Review 2.  Mice without telomerase: what can they teach us about human cancer?

Authors:  S E Artandi; R A DePinho
Journal:  Nat Med       Date:  2000-08       Impact factor: 53.440

3.  Relationship between cytogenetic aberrations by CGH coupled with tissue microdissection and DNA ploidy by laser scanning cytometry in head and neck squamous cell carcinoma.

Authors:  Y Hashimoto; A Oga; K Okami; Y Imate; Y Yamashita; K Sasaki
Journal:  Cytometry       Date:  2000-06-01

Review 4.  Mitotic checkpoints: from yeast to cancer.

Authors:  K Wassmann; R Benezra
Journal:  Curr Opin Genet Dev       Date:  2001-02       Impact factor: 5.578

5.  Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases.

Authors:  D G Skinner; R B Colvin; C D Vermillion; R C Pfister; W F Leadbetter
Journal:  Cancer       Date:  1971-11       Impact factor: 6.860

6.  The relationship of DNA ploidy to chromosomal instability in primary human colorectal cancers.

Authors:  M Miyazaki; T Furuya; A Shiraki; T Sato; A Oga; K Sasaki
Journal:  Cancer Res       Date:  1999-10-15       Impact factor: 12.701

7.  Quantitative analysis of telomerase activity and telomerase reverse transcriptase expression in renal cell carcinoma.

Authors:  T Hara; T Noma; Y Yamashiro; K Naito; A Nakazawa
Journal:  Urol Res       Date:  2001-02

Review 8.  Role of telomerase in normal and cancer cells.

Authors:  M Meyerson
Journal:  J Clin Oncol       Date:  2000-07       Impact factor: 44.544

9.  Telomere dysfunction and evolution of intestinal carcinoma in mice and humans.

Authors:  K L Rudolph; M Millard; M W Bosenberg; R A DePinho
Journal:  Nat Genet       Date:  2001-06       Impact factor: 38.330

10.  Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice.

Authors:  S E Artandi; S Chang; S L Lee; S Alson; G J Gottlieb; L Chin; R A DePinho
Journal:  Nature       Date:  2000-08-10       Impact factor: 49.962

View more
  6 in total

1.  Laser scanning cytometry: principles and applications.

Authors:  Piotr Pozarowski; Elena Holden; Zbigniew Darzynkiewicz
Journal:  Methods Mol Biol       Date:  2006

Review 2.  Laser scanning cytometry: principles and applications-an update.

Authors:  Piotr Pozarowski; Elena Holden; Zbigniew Darzynkiewicz
Journal:  Methods Mol Biol       Date:  2013

3.  Telomerase activity and genetic alterations in primary breast carcinomas.

Authors:  Anna Papadopoulou; Theoni Trangas; Manuel R Teixeira; Sverre Heim; Euthimios Dimitriadis; Haroula Tsarouha; Johan A Andersen; Evangelos Evangelou; Panayiotis Ioannidis; Niki J Agnantis; Nikos Pandis
Journal:  Neoplasia       Date:  2003 Mar-Apr       Impact factor: 5.715

4.  Genome-wide profiling of chromosomal alterations in renal cell carcinoma using high-density single nucleotide polymorphism arrays.

Authors:  Meng Chen; Yuanqing Ye; Hushan Yang; Pheroze Tamboli; Surena Matin; Nizar M Tannir; Christopher G Wood; Jian Gu; Xifeng Wu
Journal:  Int J Cancer       Date:  2009-11-15       Impact factor: 7.396

5.  A non-diploid DNA status is linked to poor prognosis in renal cell cancer.

Authors:  Franziska Büscheck; Christoph Fraune; Martina Kluth; Maximilian Lennartz; Ronald Simon; Claudia Hube-Magg; Christian Morlock; Silvano Barbieri; Carolin Wahl; Christian Eichelberg; Christina Möller-Koop; Doris Höflmayer; Corinna Wittmer; Waldemar Wilczak; Guido Sauter; Margit Fisch; Till Eichenauer; Michael Rink
Journal:  World J Urol       Date:  2020-05-02       Impact factor: 4.226

6.  Chromosomal disruption and rearrangements during murine sarcoma development converge to stable karyotypic formation kept by telomerase overexpression.

Authors:  Robson José de Oliveira-Júnior; Carlos Ueira-Vieira; Angela Aparecida Servino Sena; Carolina Fernandes Reis; José Roberto Mineo; Luiz Ricardo Goulart; Sandra Morelli
Journal:  J Biomed Sci       Date:  2016-02-03       Impact factor: 8.410

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.